People who score high on intelligence tests are also good at keeping time, new Swedish research shows. The team that carried out the study also suspect that accuracy in timing is important to the brain processes responsible for problem solving and reasoning.

Researchers at the medical university Karolinska Institutet and Umeå University have now demonstrated a correlation between general intelligence and the ability to tap out a simple regular rhythm. They stress that the task subjects performed had nothing to do with any musical rhythmic sense but simply measured the capacity for rhythmic accuracy. Those who scored highest on intelligence tests also had least variation in the regular rhythm they tapped out in the experiment.

HONG KONG, SAO PAULO, Brazil, SHANGHAI, China and PHILADELPHIA, April 16 /PRNewswire/ --

- Strategic Alliances with Roche and Pfizer Provide Portfolio of Over 20 Products -

moksha8, Inc. announced today strategic partnerships with Roche and Pfizer, the launch of over twenty products and establishment of its Latin America headquarters in Sao Paulo, Brazil. moksha8 is committed to providing the highest quality medicine to the fastest growing markets of the world, with an initial focus on Asia, Latin America and Eastern Europe.

RESEARCH TRIANGLE PARK, North Carolina, April 16 /PRNewswire/ --

Quintiles Transnational Corp. today announced the appointment of Oren Cohen, M.D. as Senior Vice President, Clinical Research Strategies.

Most recently, Cohen held the position of Chief Medical and Scientific Officer. In his new role, Cohen will be responsible for evaluating and implementing new clinical research strategies, part of the company's "shape the future" objective. He also will continue to serve as Managing Director of Quintiles Public Health and Government Services.

There is continual debate taking place over whether organisms are the result of intelligent design or evolution. The proponents of intelligent design believe that chance and selection are too casual and slow to allow complex new properties to arise. In particular, they argue that the intermediate steps in shuffling the genes to make something new are likely to scramble the existing system and be bad for the organism, e.g., "half an eye is bad for you."

A study directed by Mark Isalan, leader of the group Gene Network Engineering and Luis Serrano, coordinator of the research programme Systems Biology and leader of the group Design of Biological Systems from the Centre for Genomic Regulation in Barcelona, Spain, says that although it may seem incredible that organisms could be able to face extreme mutation processes and gene reorganization, that is just what happens.

DUBLIN, Ireland, April 16 /PRNewswire/ --

- DomainsBot extensive "name spinner" Internet address search and suggestion tool now includes .mobi domains

dotMobi, the consortium behind .mobi -- the only Internet address created specifically for mobile phones -- today announced that DomainsBot, the leading domain name suggestion and search engine company, will now include .mobi in their domain name search and suggestion tool, used by the majority of the world's best-known Internet domain name retailers, including GoDaddy, Tucows and Register.com.

EXTON, Pennsylvania, April 16 /PRNewswire/ --

- Upon Marketing Authorization Orphan Status Would Provide for Ten Years of Market Exclusivity in the European Union for Both Investigational Treatments

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the European Commission has granted orphan drug status to the monoclonal antibodies - farletuzumab (also known as MORAb-003) for the treatment of ovarian cancer and MORAb-009 for the treatment of pancreatic cancer.

SHELTON, Connecticut, April 16 /PRNewswire/ --

- Expanded and more dynamic reporting for all audiences

Computershare Limited (ASX: CPU) announced today the release of the Global Entity Management System application, version 6.1 (GEMS v6.1). This is the first version of the application to be released through Computershare Governance Services, a business unit that was formed by combining the acquisition of the Datacare Software Group with Computershare's World Records business.

A key feature of GEMS v6.1 is the addition of the advanced reporting module. Using a "drag and drop" approach, the module allows administrators to produce and format reports from information in customized fields, as well as from the standard fields.

DENVER, April 16 /PRNewswire/ --

Altira Group LLC -- the pioneer and leader in venture capital and private equity funding for energy technology companies -- announced today an investment in Hyperion Power Generation, Inc. (HPG), of Santa Fe, New Mexico. HPG is developing a new type of small, self-contained, transportable nuclear power reactor to produce heat, steam and electricity for a variety of commercial applications that require reliable power independent of the common grid.

Altira's investment in HPG was made out of the recently closed Altira Technology Fund V -- a US$176 Million fund focused on venture capital for energy technologies.

A new study shows that wetland regions emitted significantly less methane during glacial times while methane emissions by forest fire activity remained surprisingly constant from glacial to interglacial times.

Using novel isotopic studies, scientists from the European Project for Ice Coring In Antarctica (EPICA) say this identifies the most important processes responsible for changes in natural methane concentrations over the transition from the last ice age into our warm period.

Ice cores are essential for climate research because they represent the only archive which allows direct measurements of atmospheric composition and greenhouse gas concentrations in the past.

CALGARY, Canada, April 16 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan Melcher and his research group at St. James's University Hospital in Leeds, U.K. published the results of their work in the April 10 online issue of Gene Therapy. The paper is entitled "Inflammatory Tumour Cell Killing by Oncolytic Reovirus for the Treatment of Melanoma."

The investigators showed that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour. They demonstrated that reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death. They concluded that reovirus is suitable for clinical testing in melanoma.